

**BVF Partners L.P.
One Sansome Street, 30th Floor
San Francisco, California 94104**

17 November 2017

**RE: Declaration pursuant to Article 13 of Law Decree No. 148 of 16
October 2017, amending Article 120 of Legislative Decree No.
58/1998**

Dear Sirs,

We make reference to the major holding disclosure form filed with CONSOB on 13 November 2017 pursuant to Article 120, paragraph 2, of Legislative Decree No. 58/1998 and relating to the crossing upward of the 20% threshold of the share capital of the company CTI BioPharma Corp. ("CTI" or the "Company").

The disclosure was given by Mr Mark N. Lampert, in its capacity as person at the top of the chain of control of BVF Partners L.P., that is (a) the general partner of the limited partnerships Biotechnology Value Fund L.P. and Biotechnology Value Fund II L.P., (b) the sole beneficial owner of the


general partner of Biotechnology Value Trading Fund OS L.P. and (c) the investment advisor of certain managed accounts, which directly hold the equity interests subject matter of the disclosure above (all the entities involved, collectively, the “**BVF Group**” or “**BVF**”).

Pursuant to Article 13 of Law Decree No. 148 of 16 October 2017, the undersigned hereby declares the following:

- (i) *Financial Resources*: The crossing upward of the 20% threshold of the share capital of CTI was not due to an active trade, but rather occurred as a consequence of a change in the share capital of CTI. In particular, the crossing of the threshold was due to the cancellation of a total of approximately 17,000 shares by CTI over time, culminating in the new share capital as of 30 October 2017, made public on 7 November 2017, which determined the crossing of the 20% threshold. As such, there was no acquisition by the BVF Group and there were no financial resources used in conjunction with BVF's ownership in CTI increasing above 20%.
- (ii) *Concert with Others*: As mentioned in point (i) above, the BVF Group did not actively trade to acquire a greater ownership percentage of CTI. As such, there was no action made in concert with others.
- (iii) *Further Purchases / Strategies*: the BVF Group had no intention prior to the Company's adjustment of its outstanding shares, nor does it have at the date hereof, to acquire additional shares of CTI. BVF also has no intention of exercising an influence on the management of the Company. BVF maintains that it is a passive investor in the Company and has no intention to become an activist investor.
- (iv) *Agreements*: BVF's intentions with respect to the agreements to which it is a party have not changed as a result of the change in share capital of CTI. BVF maintains that it is a passive investor in the Company and has no intention to become an activist investor.
- (v) *Management and Control Bodies*: BVF maintains that it is a passive investor in the Company and has no intention to date to exert any measure of control over the Company, its employees or its Board of Directors, nor to supplement or terminate the management and control bodies of the Company.

For any clarification, please do not hesitate to contact: James Kratky at BVF (tel: +1 415 525 8830, e-mail: kratky@bvflp.com) or our Italian legal counsel Marco Zaccagnini (tel: +44 (0)20 739 7 1717, e-mail: mzaccagnini@gop.it) and Maria Rosa Piluso (tel: +44 (0)20 739 7 1713, e-mail: mrpiluso@gop.it).

Kind Regards,

A handwritten signature in black ink, appearing to read 'M. Lampert', is written over a horizontal line.

Mark N. Lampert